Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide
- 1 June 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (11) , 7376-7382
Abstract
Despite evidence that points to unfettered hyaluronic acid (HA) production as a culprit in the progression of rheumatic disorders, little is known about differences in regulation and biological functions of the three hyaluronan synthase (HAS) genes. Testing the effects of drugs with proven anti-inflammatory effects could help to clarify biological functions of these genes. In this study, we demonstrate that leflunomide suppresses HA release in fibroblast-like synoviocytes (FLS) in a dose-dependent manner. We further demonstrate that leflunomide suppresses HA synthase activity, as determined by 14C-glucuronic acid incorporation assays. Additional experiments revealed that in FLS, leflunomide specifically blocked the induction of HAS1. HAS2 and HAS3, genes that are, in contrast to HAS1, constitutively expressed in FLS, are not significantly affected. Leflunomide can function as a NF-κB inhibitor. However, EMSA experiments demonstrate that at the concentrations used, leflunomide neither interferes with IL-1β- nor with PMA-induced NF-κB translocation. Furthermore, reconstituting the pyrimidine synthase pathway did not lead to the restoration of IL-1β-induced HAS1 activation. More importantly, two tyrosine kinase inhibitors mimicked the effect of leflunomide in that both blocked IL-1β-induced HAS1 activation without affecting HAS2 or HAS3. These data point at HAS1 activation as the possible cause for unfettered HA production in rheumatoid arthritis and might explain, at least in part, the beneficial effects of leflunomide treatment. These findings also support the concept that IL-1β-induced HAS1 activation depends on the activation of tyrosine kinases, and indicate that leflunomide blocks HA release by suppressing tyrosine kinases rather than through inhibition of NF-κB translocation.Keywords
This publication has 51 references indexed in Scilit:
- Hyaluronan and Angiogenesis2007
- Leflunomide: mode of action in the treatment of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- Expression and Activity of Articular Cartilage HyaluronidasesBiochemical and Biophysical Research Communications, 1998
- Serum Hyaluronan as a Disease MarkerAnnals of Medicine, 1996
- Tyrosine Kinase Inhibitors, Genistein and Herbimycin A, Do Not Block Interleukin-1 β-Induced Activation of NF-κB in Rat Mesangial CellsBiochemical and Biophysical Research Communications, 1996
- Hyaluronidases - a group of neglected enzymesProtein Science, 1995
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994
- Animal Models of Rheumatoid ArthritisClinical Orthopaedics and Related Research, 1991
- Effect of capsaicin on the release of substance P from rheumatoid arthritis and osteoarthritis synoviocytes in vitro.Annals of the Rheumatic Diseases, 1990
- Etiology of rheumatoid arthritisCellular and Molecular Life Sciences, 1985